(Q44037646)

29 November 2017

title

Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML. (English)

1 reference

29 November 2017

Horn B

1

1 reference

29 November 2017

Baxter-Lowe LA

2

1 reference

29 November 2017

Englert L

3

1 reference

29 November 2017

McMillan A

4

1 reference

29 November 2017

Quinn M

5

1 reference

29 November 2017

Desantes K

6

1 reference

29 November 2017

Cowan M

7

1 reference

29 November 2017

language of work or name

English

0 references

publication date

1 February 2006

1 reference

Bone Marrow Transplantation

29 November 2017

published in

1 reference

29 November 2017

volume

37

1 reference

29 November 2017

issue

3

1 reference

29 November 2017

page(s)

263-269

1 reference

Bone marrow transplantation for sickle cell disease.

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705240

Hematopoietic cell transplantation for inherited metabolic diseases: an overview of outcomes and practice guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705240

Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705240

Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705240

Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705240

Reduced-intensity allogeneic stem cell transplantation in adults and children with malignant and nonmalignant diseases: end of the beginning and future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705240

Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705240

Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705240

Phase II study of a moderate-intensity preparative regimen with allogeneic peripheral blood stem cell transplantation for hematologic diseases: the Texas Transplant Consortium experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705240

A pilot study of reduced intensity conditioning and allogeneic stem cell transplantation from unrelated cord blood and matched family donors in children and adolescent recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705240

Reduced intensity haemopoietic stem-cell transplantation for treatment of non-malignant diseases in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705240

Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705240

Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705240

Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705240

A novel reduced-intensity stem cell transplant regimen for nonmalignant disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705240

Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968–99

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705240

Reproductive status in long-term bone marrow transplant survivors receiving busulfan-cyclophosphamide (120 mg/kg)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705240

inferred from DOI database lookup

7 January 2021

based on heuristic

Ovarian function after autologous bone marrow transplantation in childhood: high-dose busulfan is a major cause of ovarian failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705240

inferred from DOI database lookup

7 January 2021

based on heuristic

Immune reconstitution after haematopoietic transplantation with two different doses of pre-graft antithymocyte globulin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705240

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.BMT.1705240

1 reference

29 November 2017

1 reference